Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
klebicin KvarM
- Development stage
- Preclinical
- Lead developer
- Nomad Bioscience
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Administration
- Oral, Intravenous
01
Overview
Klebicin KvarM is a recombinant, plant-expressed bacteriocin (specifically a colicin-like bacteriocin) developed by Nomad Bioscience and its subsidiary Nomads for the treatment and prevention of multidrug-resistant *Klebsiella* infections, including *Klebsiella pneumoniae* gastrointestinal colonization and sepsis. Derived from *Klebsiella variicola*, KvarM is a wide-spectrum bacteriocin that exhibits targeted antimicrobial activity against various *Klebsiella* species, including *K. pneumoniae*, *K. quasipneumoniae*, *K. variicola*, *K. oxytoca*, and *K. aerogenes*. It exerts its antibacterial effect through pore formation and peptidoglycan degradation, selectively targeting pathogenic *Klebsiella* without significantly disrupting the commensal gut microbiota. Klebicin KvarM has been evaluated in preclinical murine models of gastrointestinal tract infection (using a pH-dependent Eudragit-coated oral formulation for targeted release in the small and large intestines) and sepsis (via intravenous administration).
- Other names
- bacteriocin KvarMklebicin-KvarMrecombinant bacteriocin KvarM
02
Targets
ExbB (Biopolymer transport protein ExbB)FhuA (Ferrichrome outer membrane transporter)Lipid IITonB (TonB energy transducer protein)
Beyond the preview
Go deeper on klebicin KvarM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on klebicin KvarM.